GENDER DIFFERENCES IN TISSUE CASCADE OF ACTIVATION OF PLASMINOGEN AND PAI-1 IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Aim: comparative analysis of uPA-Ag, uPA-act, tPA-Ag, tPA-act, PAI-1-Ag and PAI-1-act in tissues of esophageal squamous cell carcinoma (ESCC) in men (M) and women (W) to clarify some pathogenesis issues. Material and methods. Tumor tissue of ESCC and its perifocal area (19 M and 8 menopausal W aged 38 - 72 years, st II, G2, T2-3N0-1M0-1) were studied by ELISA using standard test kits. Results. ESCC tissue of M showed an increase in both uPA types from the resection line (RL), while in W only uPA-act was increased. tPA-Ag was decreased in tumors of W, tPA-act - in tumors of all patients. Levels of both PAI-1 types were higher in ESCC of M than in W. In M, tPA-Ag in perifocal area was lower than in RL, while in W, on the contrary, it was higher. tPA-Ag/tPA-act coefficient in M tumors was 5.7 times higher than in W; in perifocal area it was reduced in all patients, being at the same time in M lower than in W. Both PAI-1 types were increased in malignant tissues of all patients, prevailing in M tumors, and PAI-1-Ag in peritumoral tissue was higher in M than in W. Conclusions. Significant gender differences were found in expression of uPA, tPA and PAI-1 in tissues of esophageal squamous cell carcinoma. Presence of tumor-associated uPA, PAI-1 and tPA in men and uPA and PAI-1 in women is possible in tumor tissue of esophageal squamous cell carcinoma and its perifocal area. Determination of plasminogen regulation system in tissues of esophageal squamous cell carcinoma can be used for the selection and individualization of postoperative treatments.

uPA, tPA, PAI-1, squamous cell carcinoma of the esophagus, uPA, tPA, PAI-1, gender differences

1. Tihan T., Harmon J. W., Wan X. et al. Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus. Anticancer Res. 2001; 21: 3107 - 3114.

2. Sukocheva O. A., Li B., Due S. L. et al. Androgens and esophageal cancer: What do we know? World. J. Gastroenterol. 2015; 21 (20): 6146 - 6156.

3. Duffy M. J., McGowan P. M., Harbeck N. et al. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014; 16 (4): 428.

4. Asuthkar S., Stepanova V., Lebedeva T. et al. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol. Biol. Cell. 2013; 24 (17): 2620 - 2632.

5. Wang JG, Geddings JE, Aleman MM. et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012; 119 (23): 5543 - 5552.

6. Geddings J. E., Hisada Y., Boulaftali Y. et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J. Thromb. Haemost. 2016; 14 (1): 153 - 166.

7. Aĭsina R. B., Mukhametova L. I. [Structure and functions of plasminogen/plasmin system]. Bioorg. Khim. 2014; 40 (6): 642 - 657. Review. Russian.

8. Huang C., Xie D., Cui J. et al. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin. Cancer Res. 2014; 20 (6): 1477 - 1488.

9. Witzel I., Milde-Langosch K., Schmidt M. et al. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco. Targets Ther. 2014; 28 (7): 2205 - 2213.

10. Del Rosso M., Margheri F., Serratì S. et al. The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Current Pharmaceutical Design. 2011; 17 (19): 1924 - 1943.

11. Schuliga M. The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm. 2015; 2015: 4376 - 4395.

12. Schardt F. W., Schmausser B., Bachmann E. Monoclonal antibodies for immunodetection of fibrin deposits on cancer cells. Histology and Histopathology. 2013; 28 (8): 993 - 998.

13. Yang D., Kuan C. Y. Anti-tissue Plasminogen Activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation. CNS Neuroscience & Therapeutics. 2014.

14. Франциянц Е. М., Комарова Е. Ф., Верескунова М. И., Черярина Н. Д. Состояние тканевой фибринолитической системы при опухолях органов женской репродуктивной системы. Успехи современного естествознания. 2014; (4): 46 - 48.

15. Xiao W., Hsu Y.-P., Ishizaka A. et al. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest. 2005; 128 (4): 2316 - 2326.

16. Ma Z., Paek D., Oh C. K. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clinical and Experimental Allergy. 2009; 39 (8): 1136 - 1144.

17. Iwaki T., Urano T., Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. British Journal of Haematology. 2012; 157 (3): 291 - 298.

18. Yang L. F., Ji X. G., Xing M. D. et al. The relationship between esophageal cancer and androgen-estrogen receptors. Zhongguo Xiongxinxieguan Waike Linchuang Zazhi. 2001; 8: 154 - 156.

19. Flüchter S. H., Weiser R., Gamper C. The role of hormonal treatment in prostate cancer. Recent Results Cancer Res. 2007; 175: 211 - 237.

20. Levin E. R., Pietras R. J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 2008; 108: 351 - 361.

21. Cook M. B., Wood S. N., Cash B. D. et al. Association between circulating levels of sex steroid hormones and Barrett’s esophagus in men: a case-control analysis. Clin. Gastroenterol. Hepatol. 2015; 13: 673 - 682.

22. Cooper S. C., Trudgill N. J. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database. Cancer Causes Control. 2012; 23: 819 - 825.

23. Tang L., Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomedicine and Pharmacotherapy. 2013; 67 (2): 179 - 182.

24. Chen H., Peng H., Liu W. et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery. 2015; 158 (6): 1704 - 1713.

25. Schuliga M., Langenbach S., Xia Y. C., et al. Plasminogen-stimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2. The American Journal of Respiratory Cell and Molecular Biology. 2013; 49 (5): 751 - 758.

26. Kwaan H. C., McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treatment and Research. 2009; 148: 43 - 66.

27. Shimomura M., Hinoi T., Ikeda S. et al. Preservation of peritoneal fibrinolysis owing to decreased transcription of plasminogen activator inhibitor-1 in peritoneal mesothelial cells suppresses postoperative adhesion formation in laparoscopic surgery. Surgery. 2013; 153 (3): 344 - 356.

28. Stewart A. G., Xia Y. C., Harris T. et al. Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling. British Journal of Pharmacology. 2013; 170 (7): 1421 - 1435.